Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
AssigneePalleon Pharmaceuticals Inc.
InventorsLi Peng, Sandip A. Shelke, Lizhi Cao
Life of this patent
Estimating the term…
Abstract
The invention relates generally to recombinant sialidases (for example, recombinant sialidases having reduced protease sensitivity), recombinant fusion proteins, and antibody conjugates, and their use in the treatment of cancer.
Claims61
A recombinant mutant sialidase enzyme (e.g., human sialidase enzyme), wherein the sialidase comprises a mutation that increases resistance to cleavage by a protease.
A recombinant mutant human sialidase enzyme, wherein the sialidase comprises:
- (a) a substitution of a proline residue at a position corresponding to position 5 of wild-type human Neu2 (P5);
- (b) a substitution of a lysine residue at a position corresponding to position 9 of wild-type human Neu2 (K9);
- (c) a substitution of an alanine residue at a position corresponding to position 42 of wild-type human Neu2 (A42);
- (d) a substitution of a lysine residue at a position corresponding to position 44 of wild-type human Neu2 (K44);
- (e) a substitution of a lysine residue at a position corresponding to position 45 of wild-type human Neu2 (K45);
- (f) a substitution of a leucine residue at a position corresponding to position 54 of wild-type human Neu2 (L54);
- (g) a substitution of a proline residue at a position corresponding to position 62 of wild-type human Neu2 (P62);
- (h) a substitution of a glutamine residue at a position corresponding to position 69 of wild-type human Neu2 (Q69);
- (i) a substitution of an arginine residue at a position corresponding to position 78 of wild-type human Neu2 (R78);
- (j) a substitution of an aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 (D80);
- (k) a substitution of an alanine residue at a position corresponding to position 93 of wild-type human Neu2 (A93);
- (l) a substitution of a glycine residue at a position corresponding to position 107 of wild-type human Neu2 (G107);
- (m) a substitution of a glutamine residue at a position corresponding to position 108 of wild-type human Neu2 (Q108);
- (n) a substitution of a glutamine residue at a position corresponding to position 112 of wild-type human Neu2 (Q112);
- (o) a substitution of a cysteine residue at a position corresponding to position 125 of wild-type human Neu2 (C125);
- (p) a substitution of a glutamine residue at a position corresponding to position 126 of wild-type human Neu2 (Q126);
- (q) a substitution of an alanine residue at a position corresponding to position 150 of wild-type human Neu2 (A150);
- (r) a substitution of a cysteine residue at a position corresponding to position 164 of wild-type human Neu2 (C164);
- (s) a substitution of an arginine residue at a position corresponding to position 170 of wild-type human Neu2 (R170);
- (t) a substitution of an alanine residue at a position corresponding to position 171 of wild-type human Neu2 (A171);
- (u) a substitution of a glutamine residue at a position corresponding to position 188 of wild-type human Neu2 (Q188);
- (v) a substitution of an arginine residue at a position corresponding to position 189 of wild-type human Neu2 (R189);
- (w) a substitution of an alanine residue at a position corresponding to position 213 of wild-type human Neu2 (A213);
- (x) a substitution of a leucine residue at a position corresponding to position 217 of wild-type human Neu2 (L217);
- (y) a substitution of a glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 (E225);
- (z) a substitution of a histidine residue at a position corresponding to position 239 of wild-type human Neu2 (H239);
- (aa) a substitution of a leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240);
- (bb) a substitution of an arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241);
- (cc) a substitution of an alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242);
- (dd) a substitution of a valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244);
- (ee) a substitution of a threonine residue at a position corresponding to position 249 of wild-type human Neu2 (T249);
- (ff) a substitution of an aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 (D251);
- (gg) a substitution of a glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 (E257);
- (hh) a substitution of a serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258);
- (ii) a substitution of a leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260);
- (jj) a substitution of a valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265);
- (kk) a substitution of a glutamine residue at a position corresponding to position 270 of wild-type human Neu2 (Q270);
- (ll) a substitution of a tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 (W292);
- (mm) a substitution of a serine residue at a position corresponding to position 301 of wild-type human Neu2 (S301);
- (nn) a substitution of a tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 (W302);
- (oo) a substitution of a valine residue at a position corresponding to position 363 of wild-type human Neu2 (V363);
- or
- (pp) a substitution of a leucine residue at a position corresponding to position 365 of wild-type human Neu2 (L365);
- or a combination of any of the foregoing substitutions.
A recombinant mutant human sialidase enzyme, wherein the sialidase comprises:
- (a) a substitution of a proline residue at a position corresponding to position 5 of wild-type human Neu2 (P5);
- (b) a substitution of a lysine residue at a position corresponding to position 9 of wild-type human Neu2 (K9);
- (c) a substitution of a lysine residue at a position corresponding to position 44 of wild-type human Neu2 (K44);
- (d) a substitution of a lysine residue at a position corresponding to position 45 of wild-type human Neu2 (K45);
- (e) a substitution of a leucine residue at a position corresponding to position 54 of wild-type human Neu2 (L54);
- (f) a substitution of a proline residue at a position corresponding to position 62 of wild-type human Neu2 (P62);
- (g) a substitution of a glutamine residue at a position corresponding to position 69 of wild-type human Neu2 (Q69);
- (h) a substitution of an arginine residue at a position corresponding to position 78 of wild-type human Neu2 (R78);
- (i) a substitution of an aspartic acid residue at a position corresponding to position 80 of wild-type human Neu2 (D80);
- (j) a substitution of an alanine residue at a position corresponding to position 93 of wild-type human Neu2 (A93);
- (k) a substitution of a glycine residue at a position corresponding to position 107 of wild-type human Neu2 (G107);
- (l) a substitution of a glutamine residue at a position corresponding to position 108 of wild-type human Neu2 (Q108);
- (m) a substitution of a glutamine residue at a position corresponding to position 112 of wild-type human Neu2 (Q112);
- (n) a substitution of a cysteine residue at a position corresponding to position 125 of wild-type human Neu2 (C125);
- (o) a substitution of a glutamine residue at a position corresponding to position 126 of wild-type human Neu2 (Q126);
- (p) a substitution of an alanine residue at a position corresponding to position 150 of wild-type human Neu2 (A150);
- (q) a substitution of a cysteine residue at a position corresponding to position 164 of wild-type human Neu2 (C164);
- (r) a substitution of an arginine residue at a position corresponding to position 170 of wild-type human Neu2 (R170);
- (s) a substitution of an alanine residue at a position corresponding to position 171 of wild-type human Neu2 (A171);
- (t) a substitution of a glutamine residue at a position corresponding to position 188 of wild-type human Neu2 (Q188);
- (u) a substitution of an arginine residue at a position corresponding to position 189 of wild-type human Neu2 (R189);
- (v) a substitution of an alanine residue at a position corresponding to position 213 of wild-type human Neu2 (A213);
- (w) a substitution of a leucine residue at a position corresponding to position 217 of wild-type human Neu2 (L217);
- (x) a substitution of a glutamic acid residue at a position corresponding to position 225 of wild-type human Neu2 (E225);
- (y) a substitution of a histidine residue at a position corresponding to position 239 of wild-type human Neu2 (H239);
- (z) a substitution of a leucine residue at a position corresponding to position 240 of wild-type human Neu2 (L240);
- (aa) a substitution of an arginine residue at a position corresponding to position 241 of wild-type human Neu2 (R241);
- (bb) a substitution of an alanine residue at a position corresponding to position 242 of wild-type human Neu2 (A242);
- (cc) a substitution of a valine residue at a position corresponding to position 244 of wild-type human Neu2 (V244);
- (dd) a substitution of a threonine residue at a position corresponding to position 249 of wild-type human Neu2 (T249);
- (ee) a substitution of an aspartic acid residue at a position corresponding to position 251 of wild-type human Neu2 (D251);
- (ff) a substitution of a glutamic acid residue at a position corresponding to position 257 of wild-type human Neu2 (E257);
- (gg) a substitution of a serine residue at a position corresponding to position 258 of wild-type human Neu2 (S258);
- (hh) a substitution of a leucine residue at a position corresponding to position 260 of wild-type human Neu2 (L260);
- (ii) a substitution of a valine residue at a position corresponding to position 265 of wild-type human Neu2 (V265);
- (jj) a substitution of a glutamine residue at a position corresponding to position 270 of wild-type human Neu2 (Q270);
- (kk) a substitution of a tryptophan residue at a position corresponding to position 292 of wild-type human Neu2 (W292);
- (ll) a substitution of a serine residue at a position corresponding to position 301 of wild-type human Neu2 (S301);
- (mm) a substitution of a tryptophan residue at a position corresponding to position 302 of wild-type human Neu2 (W302);
- (nn) a substitution of a valine residue at a position corresponding to position 363 of wild-type human Neu2 (V363);
- or
- (oo) a substitution of a leucine residue at a position corresponding to position 365 of wild-type human Neu2 (L365);
- or a combination of any of the foregoing substitutions.
A recombinant mutant human sialidase comprising a mutation or combination of mutations set forth in any one of TABLES 1, 2, 7-9, 11-13, 15-30, 34, or 35, and optionally further comprising a mutation or combination of mutations set forth in any one of TABLES 3-6.
Dependencies are inferred from the claim text.